2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Pathology, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Checkpoint Inhibitor, Monoclonal Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Generative AI, Natural Language Processing, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, LGL, Non-Hodgkin Lymphoma, T Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult
PAPER

5375 Relapse patterns and management strategies for peripheral T-cell lymphoma following ASCT failure: A real-world analysis in the era of novel agents

Jiajie Tu, MBBS, Rui Zou2, Ping Nana3, Qian Zhu4, Junhong Li5, Xiao Zhang6, Depei Wu7, Zhengming Jin8, Changju Qu9
1 Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China, Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, Jiangsu Province, China, National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China
2 Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China, Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, Jiangsu Province, China, National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China
3 Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China, Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, Jiangsu Province, China, National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China
4 Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China, Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, Jiangsu Province, China, National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China
5 Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China, Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, Jiangsu Province, China, National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China
6 Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China, Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, Jiangsu Province, China, National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China
7 Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China, Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, Jiangsu Province, China, National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China
8 Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China, Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, Jiangsu Province, China, National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China
9 Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China, Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, Jiangsu Province, China, National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China

Background: Autologous stem cell transplantation (ASCT) is recommended for first-remission consolidation in peripheral T-cell lymphoma (PTCL) despite the absence of randomized trial evidence. However, managing post-ASCT failure remains a major clinical challenge. The era of novel agents (NAs), beginning with U.S. Food and Drug Administration approvals of romidepsin and brentuximab vedotin (BV) in 2011, has introduced new therapeutic options, but the role of NAs in this setting requires further characterization.

Methods: This study included PTCL patients who underwent ASCT at our center between 2015 and 2025. Part I evaluated the entire cohort for progression-free survival (PFS) and overall survival (OS). Part II focused on a sub-cohort experiencing post-ASCT relapse or progression. NAs utilized included BV, chidamide, azacitidine, golidocitinib, linperlisib, pembrolizumab, and others. Primary endpoints for the sub-cohort were PFS2 and OS2; secondary endpoints included overall response rate (ORR), complete response rate (CRR) and non-relapse mortality (NRM). PFS2 was measured from the initiation of treatment to the date of progressive disease (PD) or death from any cause. OS2 was measured from the date of ASCT failure to death from any cause. Survival probabilities were estimated using the Kaplan–Meier method, with differences tested by log-rank for PFS, OS, PFS2 and OS2. Group comparisons of NRM were performed using Gray's test to account for competing risks. The Lugano (2014) criteria were employed for assessing treatment outcomes.

Results: A total of 113 PTCL patients were included (median age 50 years; PTCL-NOS 28.3%, AITL 24.8%, NK/T 24.8%), consisting of 73 who underwent up-front ASCT (94.5% in CR1) and 40 who underwent salvage ASCT (55.0% in ≥CR2, 17.5% in stable disease [SD]/PD). In the whole cohort (median follow-up, 50.8 months), 4-year PFS and OS rates were 53.2% and 72.3%. Up-front ASCT demonstrated a superior 4-year OS compared to salvage ASCT (80.7% vs. 57.8%; P = 0.020), while PFS was comparable (4-year, 57.9% vs. 45.3%; P = 0.590). SD/PD was associated with inferior PFS (P = 0.005) and OS (P = 0.020) for salvage cohort. Forty-seven patients (median age 52 years, range 23 – 69) experienced relapse or progression after ASCT, encompassing PTCL-NOS 29.8%, AITL 27.7%, NK/T 19.1% and ALCL 12.8%. Of these patients, 36 were treated with NA-based regimens, one received chemotherapy, and 10 were managed with only symptomatic and supportive treatment without systemic therapy. For the whole ASCT failure sub-cohort (n = 47), the CRR and ORR were 53.2% and 61.7%, the median PFS2 and OS2 were 28.0 and 36.6 months and the 3-year PFS2 and OS2 were 44.3% and 53.2% (median follow-up, 40.0 months). For patients who received chemotherapy or no systemic therapy (chemotherapy/none group, n=11), no response was observed and all died within 3 months. For patients receiving NA-based treatments (n=36), the CRR and ORR were 69.4% and 80.6%, and the 3-year PFS2 and OS2 rates were 57.8% and 69.4%. Among the 36 patients with NA-based treatments, 29 received only NA-based treatments (NA-NA group) and 7 bridging to allogeneic stem cell transplantation (allo-HSCT) (NA-allo-HSCT group). With similar baseline characteristics, the NA-NA group (median follow-up, 41.0 months) achieved comparable PFS2 and OS2 compared to the NA–allo-HSCT group (median follow-up, 40.0 months) (3-year PFS2, 52.3% vs 80.0%; P=0.093) (3-year OS2, 66.9% vs 80.0%; P = 0.290). Compared with the chemotherapy/none group, which had a higher proportion of patients with International Prognostic Index scores 2–4 (58.6% vs. 100%; P = 0.017) and Eastern Cooperative Oncology Group performance status 2–3 (10.3% vs. 63.6%; P = 0.002), the NA-NA group achieved markedly superior OS2 (median, not reached vs 0.4 months; 3-year, 66.9% vs. 0%; P < 0.001). For safety, NRM was comparable between the NA-NA group and NA–allo-HSCT group (40.0 months, 3.8% vs. 0%; P = 0.510).

Conclusions: Pre-ASCT SD/PD identifies patients with poor ASCT outcomes. In the NA era, PTCL patients failing ASCT have substantially improved prospects. NA-based regimens effectively bridge patients to allo-HSCT, which may offer curative potential for eligible candidates, whereas sequential NA-based therapy provides effective disease control with low-NRM for transplant-ineligible patients, representing a promising alternative option. These findings warrant further exploration.
Jiajie Tu, MBBS: No relevant conflicts of interest to declare.